Corporate/Strategic alliances
Neurim Pharmaceuticals market its new drugs through strategic alliances with reputable marketing and distribution partners on whose marketing expertise we rely.
Currently Neurim has established marketing and distribution agreements with:

NYCOMED
Nycomed will market Circadin® in Belgium, Netherlands, Austria, Greece, the Baltic States, Norway, Sweden, Finland, Denmark, Iceland, Luxembourg and Russia-CIS.  Circadin® was launched in Denmark on 8 October  2007.
Nycomed provides products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. The company is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New products are sourced both from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region Nycomed has a presence in about 50 markets worldwide.
Privately owned, the combined group had non-audited estimated annual sales of approximately € 3.4 billion and an EBITDA of € 933.4 million (2006 results).
For more information visit www.nycomed.com

LUNDBECK
Lundbeck in-licensed the exclusive rights for Circadin® for the treatment of primary insomnia for the majority of markets in Europe including the five major markets. Furthermore, Lundbeck holds the exclusive option to evaluate commercialization in markets outside of Europe.
H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company’s revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com.